Zedoarondiol
Based on 1 Customer Validation
Zedoarondiol, a sesquiterpene lactone compound, with antioxidant and anti-inflammatory activity. Zedoarondiol can be used for atherosclerosis research.
For research use only. We do not sell to patients.
- Purity: 98.99%
- CAS No.: 98644-24-7
- Formula: C15H24O3
- Molecular Weight:252.35
-
Storage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Zedoarondiol (5-20 μg/mL) attenuates HUVECs injury, up-regulated SOD activity, suppressed formation of MDA and ROS, and secretion and protein expression of IL-1β, TNF-α, and MCP-1 in injured HUVECs induced by oxidized low-density lipoprotein (ox-LDL)[1].
Zedoarondiol induces nuclear Nrf2 translocation from cytoplasm into nucleus and up-regulated expression of HO-1, NQO1, and Nrf2 in nucleus[1].
Zedoarondiol suppresses PDGF-BB-induced vascular smooth muscle cells (VSMCs) proliferation and DNA synthesis, and induces cell cycle arrest in G0/G1 phase. In addition, Zedoarondiol activates AMPK and ACC, inhibited the phosphorylation of mTOR and p70S6K, increases the expression of p53 and p21, and decreases the expression of CDK2 and cyclin E[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 98644-24-7
-
Appearance Solid
-
Molecular Weight 252.35
-
Formula C15H24O3
-
Color Light yellow to yellow
-
SMILES
C[C@@]1([C@]2([H])[C@](CC1)([H])[C@@](O)(CC(/C(C2)=C(C)/C)=O)C)O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
DMSO : 50 mg/mL (198.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (4.95 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (4.95 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Huimin Mao, et al. Zedoarondiol Attenuates Endothelial Cells Injury Induced by Oxidized Low-Density Lipoprotein via Nrf2 Activation. Cell Physiol Biochem. 2018;48(4):1468-1479. [Content Brief]
[2]. Huimin Mao, et al. Zedoarondiol Inhibits Platelet-Derived Growth Factor-Induced Vascular Smooth Muscle Cells Proliferation via Regulating AMP-Activated Protein Kinase Signaling Pathway. Cell Physiol Biochem. 2016;40(6):1506-1520. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.9628 mL | 19.8138 mL | 39.6275 mL | 99.0688 mL |
| 5 mM | 0.7926 mL | 3.9628 mL | 7.9255 mL | 19.8138 mL | |
| 10 mM | 0.3963 mL | 1.9814 mL | 3.9628 mL | 9.9069 mL | |
| 15 mM | 0.2642 mL | 1.3209 mL | 2.6418 mL | 6.6046 mL | |
| 20 mM | 0.1981 mL | 0.9907 mL | 1.9814 mL | 4.9534 mL | |
| 25 mM | 0.1585 mL | 0.7926 mL | 1.5851 mL | 3.9628 mL | |
| 30 mM | 0.1321 mL | 0.6605 mL | 1.3209 mL | 3.3023 mL | |
| 40 mM | 0.0991 mL | 0.4953 mL | 0.9907 mL | 2.4767 mL | |
| 50 mM | 0.0793 mL | 0.3963 mL | 0.7926 mL | 1.9814 mL | |
| 60 mM | 0.0660 mL | 0.3302 mL | 0.6605 mL | 1.6511 mL | |
| 80 mM | 0.0495 mL | 0.2477 mL | 0.4953 mL | 1.2384 mL | |
| 100 mM | 0.0396 mL | 0.1981 mL | 0.3963 mL | 0.9907 mL |
Zedoarondiol Related Classifications
HY-122915 Related Classifications
Powered by Bioz